{
  "id": [
    "32566260"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "32566260"
  ],
  "pmcid": [
    "PMC7293210"
  ],
  "doi": [
    "10.1038/s41541-020-0200-y"
  ],
  "title": [
    "Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice."
  ],
  "authorString": [
    "van der Fits L, Bolder R, Heemskerk-van der Meer M, Drijver J, van Polanen Y, Serroyen J, Langedijk JPM, Schuitemaker H, Saeland E, Zahn R."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "van der Fits L"
          ],
          "firstName": [
            "Leslie"
          ],
          "lastName": [
            "van der Fits"
          ],
          "initials": [
            "L"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Bolder R"
          ],
          "firstName": [
            "Renske"
          ],
          "lastName": [
            "Bolder"
          ],
          "initials": [
            "R"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Heemskerk-van der Meer M"
          ],
          "firstName": [
            "Marjolein"
          ],
          "lastName": [
            "Heemskerk-van der Meer"
          ],
          "initials": [
            "M"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Drijver J"
          ],
          "firstName": [
            "Joke"
          ],
          "lastName": [
            "Drijver"
          ],
          "initials": [
            "J"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "van Polanen Y"
          ],
          "firstName": [
            "Yolinda"
          ],
          "lastName": [
            "van Polanen"
          ],
          "initials": [
            "Y"
          ],
          "authorId": [
            {
              "_": "0000-0001-9016-9819",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Serroyen J"
          ],
          "firstName": [
            "Jan"
          ],
          "lastName": [
            "Serroyen"
          ],
          "initials": [
            "J"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Langedijk JPM"
          ],
          "firstName": [
            "Johannes P M"
          ],
          "lastName": [
            "Langedijk"
          ],
          "initials": [
            "JPM"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Schuitemaker H"
          ],
          "firstName": [
            "Hanneke"
          ],
          "lastName": [
            "Schuitemaker"
          ],
          "initials": [
            "H"
          ],
          "authorId": [
            {
              "_": "0000-0001-8563-2266",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Saeland E"
          ],
          "firstName": [
            "Eirikur"
          ],
          "lastName": [
            "Saeland"
          ],
          "initials": [
            "E"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Zahn R"
          ],
          "firstName": [
            "Roland"
          ],
          "lastName": [
            "Zahn"
          ],
          "initials": [
            "R"
          ],
          "authorId": [
            {
              "_": "0000-0003-2822-6231",
              "$": {
                "type": "ORCID"
              }
            }
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
              ]
            }
          ]
        }
      ]
    }
  ],
  "authorIdList": [
    {
      "authorId": [
        {
          "_": "0000-0001-9016-9819",
          "$": {
            "type": "ORCID"
          }
        },
        {
          "_": "0000-0001-8563-2266",
          "$": {
            "type": "ORCID"
          }
        },
        {
          "_": "0000-0003-2822-6231",
          "$": {
            "type": "ORCID"
          }
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "supporting_data",
        "altmetrics"
      ]
    }
  ],
  "journalInfo": [
    {
      "volume": [
        "5"
      ],
      "journalIssueId": [
        "2898969"
      ],
      "dateOfPublication": [
        "2020 "
      ],
      "monthOfPublication": [
        "0"
      ],
      "yearOfPublication": [
        "2020"
      ],
      "printPublicationDate": [
        "2020-01-01"
      ],
      "journal": [
        {
          "title": [
            "NPJ vaccines"
          ],
          "ISOAbbreviation": [
            "NPJ Vaccines"
          ],
          "medlineAbbreviation": [
            "NPJ Vaccines"
          ],
          "NLMid": [
            "101699863"
          ],
          "ISSN": [
            "2059-0105"
          ],
          "ESSN": [
            "2059-0105"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2020"
  ],
  "pageInfo": [
    "49"
  ],
  "abstractText": [
    "While RSV is a major cause of respiratory morbidity in infants, vaccine development is hindered by the immaturity and Th2-bias of the infant immune system and the legacy of enhanced respiratory disease (ERD) after RSV infection following immunization with formalin inactivated (FI)-RSV vaccine in earlier clinical trials. Preclinical studies have demonstrated that an adenoviral vector-based RSV F vaccine candidate (Ad26.RSV.FA2) induces Th1-biased protective immune responses, without signs of ERD upon subsequent RSV challenge. We here developed an Ad26 vector encoding the RSV F protein stabilized in its prefusion conformation (Ad26.RSV.preF). In adult mice, Ad26.RSV.preF induced superior, Th1-biased IgG2a-dominated humoral responses as compared to Ad26.RSV.FA2, while maintaining the strong Th1-biased cellular responses. Similar to adult mice, Ad26.RSV.preF induced robust and durable humoral immunity in neonatal mice, again characterized by IgG2a-dominated RSV F-binding antibodies, and high and stable virus-neutralizing titers. In addition, vaccine-elicited cellular immune responses were durable and characterized by IFN-Î³-producing CD4+ and CD8+ T cells, with a profound Th1 bias. In contrast, immunization of neonatal mice with FI-RSV resulted in IgG1 RSV F-binding antibodies associated with a Th2 phenotype, no detectable virus-neutralizing antibodies, and a Th2-biased cellular response. These results are supportive for the clinical development of Ad26.RSV.preF for use in infants."
  ],
  "affiliation": [
    "Janssen Vaccines & Prevention B.V., Leiden, The Netherlands."
  ],
  "publicationStatus": [
    "epublish"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Electronic-eCollection"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "research-article",
        "Journal Article"
      ]
    }
  ],
  "keywordList": [
    {
      "keyword": [
        "Vaccines",
        "Viral infection"
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1038/s41541-020-0200-y"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7293210"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC7293210?pdf=render"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1038/s41541-020-0200-y"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "N"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "0"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "N"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "license": [
    "cc by"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "Y"
  ],
  "tmAccessionTypeList": [
    {
      "accessionType": [
        "nct"
      ]
    }
  ],
  "dateOfCreation": [
    "2020-06-23"
  ],
  "firstIndexDate": [
    "2020-06-23"
  ],
  "fullTextReceivedDate": [
    "2020-06-23"
  ],
  "dateOfRevision": [
    "2020-06-23"
  ],
  "electronicPublicationDate": [
    "2020-06-12"
  ],
  "firstPublicationDate": [
    "2020-06-12"
  ]
}